Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Pediatr Blood Cancer. 2020 Apr 19;67(6):e28267. doi: 10.1002/pbc.28267

Figure 3. Effects of IBET-762 and trametinib in two neuroblastoma xenograft models.

Figure 3.

Xenografts were treated with: 1) vehicle (daily), 2) I-BET762 (daily, 25 mg/kg), 3) trametinib (daily, 1 mg/kg), or 4) I-BET762-trametinib. (A) Response of tumor volumes to study arms for SK-N-BE(2)C xenografts. (B) Kaplan-Meier analyses for SK-N-BE(2)C xenografts. (C) Weight change from baseline on study arms for SK-N-BE(2)C xenografts. (D-F) Response of tumor volumes (D), Kaplan-Meier analyses (E), and weight changes (F), respectively, for SK-N-AS xenografts.